Forge Biologics
The Scientist II at Forge Biologics provides leadership and executes laboratory experiments for upstream process development to advance AAV manufacturing. The role leads projects and complex experiments, supports scale-up and technology transfer activities, and mentors junior scientists. Work is performed within a cGMP facility and involves collaboration with Process Development, Manufacturing, and Quality teams to ensure compliant execution.
Headquarters
Columbus, Ohio, United States
Company Size
201-500 employees
Founded
2020
Forge Biologics is a CDMO focused on accelerating gene therapy manufacturing, specializing in high‑yield adeno‑associated virus (AAV) vector production. The company offers end‑to‑end services including process and analytical development, clinical‑to‑commercial cGMP manufacturing at a world‑class facility, and regulatory and supply‑chain support. Clients partner with Forge for scalable AAV capacity, technical expertise, and seamless program support to move therapies faster toward patients.
Forge Biologics Emphasizes Safety Culture and EHSS Leadership
24 hours ago
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria
1 week ago
May the Forge be with you: Ascidian partners with Forge Biologics to tackle Stargardt disease
Jan 13, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Forge Biologics.
Forge Biologics didn’t post a salary, so this is our estimate from similar listings.
Ascidian Therapeutics, Forge Biologics Partner to Advance Stargardt Treatment
Jan 7, 2026